On May 8, 2020, Judge Robin L. Rosenberg of the US District Court for the Southern District of Florida appointed Goldenberg Lauricella Partner Marlene Goldenberg to the Plaintiffs’ Steering Committee as part of the leadership structure for the Zantac Multidistrict Litigation (MDL). Marlene is currently serving on the Plaintiffs’ Executive Committee for the Valsartan, Losartan, and Irbesartan MDL in the District Court of New Jersey and previously served as the head of the discovery committee for the Abilify MDL in the Northern District of Florida. Marlene and Goldenberg Lauricella look forward to holding the manufacturers of Zantac accountable for their actions.
Zantac FDA Recall
Zantac is a popular heartburn medication that is also used to treat acid indigestion, sour stomach, gastroesophageal reflux disease (GERD), and ulcers. Millions of Americans have taken Zantac and its generic formulation ranitidine, which is sold over-the-counter and prescribed.
In September 2019, the FDA began to announce recalls of Zantac and ranitidine products by various manufacturers due to contamination with the probable human carcinogen N-nitrosodimethylamine (NDMA). After more than a dozen manufacturers and distributors issued recalls, the FDA finally issued a universal recall of all Zantac and ranitidine products from the US market in April 2020.
How Does Contaminated Zantac Cause Cancer?
NDMA has been classified as a probable carcinogen by global health organizations and is often given to rats in medical studies to cause cancer. NDMA is so toxic it was formerly used to produce rocket fuel and has no approved uses in the United States.
As a member of the Plaintiffs’ Executive Committee in the Valsartan, Losartan, and Irbesartan MDL, which also involves drugs contaminated with NDMA, Marlene Goldenberg has spent nearly two years immersed in litigation surrounding NDMA contamination. The prevailing science currently demonstrates that as a result of consistently taking Zantac and ranitidine, many Americans have or will develop cancer.
What Cancers Can Zantac Cause?
The medical literature suggests that NDMA in Zantac and ranitidine can cause the following types of cancer:
- Bladder Cancer
- Breast Cancer
- Colorectal / Intestinal Cancer
- Esophageal Cancer
- Gastric Cancer
- Kidney Cancer
- Liver Cancer
- Lung Cancer
- Pancreatic Cancer
- Prostate Cancer
Let Us Help
Goldenberg Lauricella is currently investigating cases where an individual has taken Zantac or ranitidine and been diagnosed with one of the cancers listed above. If you or one of your clients developed one of these cancers after taking Zantac or ranitidine, please contact us so we can discuss your legal rights.
Please feel free to contact Marlene directly at (800) 504-0281 or via email at mjgoldenberg@goldenberglaw.com.